PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination–mediated DNA repair

Cancer Discovery

Volumn 4, Issue 12, 2014, Pages 1430-1447

  Hu, Yiduo ^a,b,c   Petit, Sarah A ^a,b   Ficarro, Scott B ^a,b   Toomire, Kimberly J ^a,b   Xie, Anyong ^d   Lim, Elgene ^a   Cao, Shiliang A ^a   Park, Eunyoung ^a,b   Eck, Michael J ^a,b   Scully, Ralph ^d   Brown, Myles ^a   Marto, Jarrod A ^a,b   Livingston, David M ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 5 DIHYDROXYISOQUINOLINE; ABRA1 PROTEIN; BRCA1 PROTEIN; ISOQUINOLINE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PEPTIDES AND PROTEINS; RAD51 PROTEIN; RAP 80 PROTEIN; TALAZOPARIB; UNCLASSIFIED DRUG; VELIPARIB; CARRIER PROTEIN; MULTIPROTEIN COMPLEX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; PARP1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN BINDING; PROTEIN SUBUNIT; RAP80 PROTEIN, HUMAN;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; BREAST CANCER; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; FLOW CYTOMETRY; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MASS SPECTROMETRY; MUTANT; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECOMBINATION REPAIR; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; BREAST TUMOR; CHEMISTRY; DNA REPAIR; FEMALE; GENE EXPRESSION; GENETICS; HELA CELL LINE; HOMOLOGOUS RECOMBINATION; HUMAN CHROMOSOME; METABOLISM; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN SUBUNIT; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BRCA1 PROTEIN; BREAST NEOPLASMS; CARRIER PROTEINS; CHROMOSOMES, HUMAN; DNA DAMAGE; DNA REPAIR; FEMALE; GENE EXPRESSION; GENOMIC INSTABILITY; HELA CELLS; HOMOLOGOUS RECOMBINATION; HUMANS; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 84915749291     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0891     Document Type: Article

References (85)

1. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408: 429 - 32.
2. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007; 11: 103 - 5.
3. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002; 21: 8981 - 93.
4. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homologydirected DNA repair. Mol Cell 1999; 4: 511 - 8.
5. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 1999; 59: 1752s - 6s.
6. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171 - 82.
7. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 2006; 20: 34 - 46.
8. Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, Xia B, et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316: 1198 - 202.
9. Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007; 316: 1202 - 5.
10. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316: 1194 - 8.
11. Yu X, Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 2004; 24: 9478 - 86.
12. Coleman KA, Greenberg RA. The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection. J Biol Chem 2011; 286: 13669 - 80.
13. Hu Y, Scully R, Sobhian B, Xie A, Shestakova E, Livingston DM. RAP80-directed tuning of BRCA1 homologous recombination function at ionizing radiation-induced nuclear foci. Genes Dev 2011; 25: 685 - 700.
14. Lee I, Blom UM, Wang PI, Shim JE, Marcotte EM. Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res 2011; 21: 1109 - 21.
15. Rajesh C, Baker DK, Pierce AJ, Pittman DL. The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion. Nucleic Acids Res 2011; 39: 132 - 45.
16. Polo SE, Kaidi A, Baskcomb L, Galanty Y, Jackson SP. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J 2010; 29: 3130 - 9.
17. Gudjonsson T, Altmeyer M, Savic V, Toledo L, Dinant C, Grofte M, et al. TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes. Cell 2012; 150: 697 - 709.
18. Lai JS, Herr W. Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc Natl Acad Sci U S A 1992; 89: 6958 - 62.
19. Hatakeyama K, Nemoto Y, Ueda K, Hayaishi O. Purification and characterization of poly(ADP-ribose) glycohydrolase. Different modes of action on large and small poly(ADP-ribose). J Biol Chem 1986; 261: 14902 - 11.
20. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995; 9: 509- 20.
21. Shieh WM, Ame JC, Wilson MV, Wang ZQ, Koh DW, Jacobson MK, et al. Poly(ADP-ribose) polymerase null mouse cells synthesize ADPribose polymers. J Biol Chem 1998; 273: 30069 - 72.
22. Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADPribose) polymerase. J Biol Chem 1999; 274: 17860 - 8.
23. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997; 90: 425- 35.
24. Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol 2006; 173: 195 - 206.
25. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51: 6581 - 91.
26. Ogata N, Ueda K, Hayaishi O. ADP-ribosylation of histone H2B. Identification of glutamic acid residue 2 as the modification site. J Biol Chem 1980; 255: 7610 - 5.
27. Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T, et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997; 17: 444 - 52.
28. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH. The nuclear localization sequences of the BRCA1 protein interact with the importin- alpha subunit of the nuclear transport signal receptor. J Biol Chem 1996; 271: 32863 - 8.
29. Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M. Direct DNA binding by Brca1. Proc Natl Acad Sci U S A 2001; 98: 6086- 91.
30. Naseem R, Sturdy A, Finch D, Jowitt T, Webb M. Mapping and conformational characterization of the DNA-binding region of the breast cancer susceptibility protein BRCA1. Biochem J 2006; 395: 529- 35.
31. Simons AM, Horwitz AA, Starita LM, Griffin K, Williams RS, Glover JN, et al. BRCA1 DNA-binding activity is stimulated by BARD1. Cancer Res 2006; 66: 2012 - 8.
32. Sturdy A, Naseem R, Webb M. Purification and characterisation of a soluble N-terminal fragment of the breast cancer susceptibility protein BRCA1. J Mol Biol 2004; 340: 469 - 75.
33. Hassa PO, Haenni SS, Elser M, Hottiger MO. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 2006; 70: 789 - 829.
34. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8 - 24.
35. Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 2008; 13: 3046 - 82.
36. Ramirez CJ, Fleming MA, Potter JD, Ostrander GK, Ostrander EA. Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes. Oncogene 2004; 23: 1780 - 8.
37. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci U S A 2003; 100: 1151 - 6.
38. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996; 14: 430 - 40.
39. Kim H, Huang J, Chen J. CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 2007; 14: 710 - 5.
40. Liu Z, Wu J, Yu X. CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol 2007; 14: 716- 20.
41. Alvarez-Gonzalez R, Althaus FR. Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents. Mut Res 1989; 218: 67 - 74.
42. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517 - 28.
43. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADPribose) binds to specific domains in DNA damage checkpoint proteins . J Biol Chem 2000; 275: 40974 - 80.
44. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell 2009; 36: 365 - 78.
45. Haince JF, Kozlov S, Dawson VL, Dawson TM, Hendzel MJ, Lavin MF, et al. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem 2007; 282: 16441 - 53.
46. Panzeter PL, Realini CA, Althaus FR. Noncovalent interactions of poly(adenosine diphosphate ribose) with histones. Biochemistry 1992; 31: 1379 - 85.
47. Yan J, Kim YS, Yang XP, Li LP, Liao G, Xia F, et al. The ubiquitininteracting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 2007; 67: 6647 - 56.
48. Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease . Mol Cell Biol 1994; 14: 8096 - 106.
49. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22: 719 - 29.
50. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination . Nucleic Acids Res 2003; 31: 4959 - 64.
51. Yang YG, Cortes U, Patnaik S, Jasin M, Wang ZQ. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004; 23: 3872 - 82.
52. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Can Res 2013; 19: 5003 - 15.
53. Puget N, Knowlton M, Scully R. Molecular analysis of sister chromatid recombination in mammalian cells. DNA Repair 2005; 4: 149 - 61.
54. Nagaraju G, Odate S, Xie A, Scully R. Differential regulation of shortand long-tract gene conversion between sister chromatids by Rad51C. Mol Cell Biol 2006; 26: 8075 - 86.
55. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struc Mol Biol 2010; 17: 688- 95.
56. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141: 243- 54.
57. Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996; 87: 757 - 66.
58. Zhu Z, Chung WH, Shim EY, Lee SE, Ira G. Sgs1 helicase and two nucleases Dna2 and Exo1 resect DNA double-strand break ends. Cell 2008; 134: 981 - 94.
59. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899 - 903.
60. Tomimatsu N, Mukherjee B, Deland K, Kurimasa A, Bolderson E, Khanna KK, et al. Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions. DNA Repair 2012; 11: 441 - 8.
61. Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, et al. BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol Cell 2011; 44: 235 - 51.
62. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51- BRCA1/2. Cancer Cell 2012; 22: 106 - 16.
63. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515 - 27.
64. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006; 66: 41 - 5.
65. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999 - 1005.
66. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17: 1514 - 20.
67. Landis MD, Lehmann BD, Pietenpol JA, Chang JC. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 2013; 15: 201.
68. Dimitrov SD, Lu D, Naetar N, Hu Y, Pathania S, Kanellopoulou C, et al. Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle. Genes Dev 2013; 27: 2274 - 91.
69. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011; 5: 387 - 93.
70. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588 - 99.
71. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913 - 7.
72. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917 - 21.
73. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382 - 92.
74. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013; 49: 2972 - 8.
75. Rebbeck TR, Mitra N, Domchek SM, Wan F, Friebel TM, Tran TV, et al. Modification of BRCA1-associated breast and ovarian cancer risk by BRCA1-interacting genes. Cancer Res 2011; 71: 5792- 805.
76. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010; 42: 885 - 92.
77. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010; 42: 880 - 4.
78. Nikkila J, Coleman KA, Morrissey D, Pylkas K, Erkko H, Messick TE, et al. Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function. Oncogene 2009; 28: 1843 - 52.
79. Solyom S, Aressy B, Pylkas K, Patterson-Fortin J, Hartikainen JM, Kallioniemi A, et al. Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med 2012; 4: 122ra23.
80. Solyom S, Patterson-Fortin J, Pylkas K, Greenberg RA, Winqvist R. Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families. Breast Cancer Res Treat 2010; 120: 165 - 8.
81. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, et al. Basal-like breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival . Breast Cancer Res Treat 2012; 133: 865 - 80.
82. Wu J, Liu C, Chen J, Yu X. RAP80 protein is important for genomic stability and is required for stabilizing BRCA1-A complex at DNA damage sites in vivo. J Biol Chem 2012; 287: 22919 - 26.
83. Yin Z, Menendez D, Resnick MA, French JE, Janardhan KS, Jetten AM. RAP80 is critical in maintaining genomic stability and suppressing tumor development. Cancer Res 2012; 72: 5080 - 90.
84. Castillo A, Paul A, Sun B, Huang TH, Wang Y, Yazinski SA, et al. The BRCA1-interacting protein abraxas is required for genomic stability and tumor suppression. Cell Rep 2014; 8: 807 - 17.
85. Xie A, Puget N, Shim I, Odate S, Jarzyna I, Bassing CH, et al. Control of sister chromatid recombination by histone H2AX. Mol Cell 2004; 16: 1017 - 25.